^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    decitabine

    i
    Other names: DAC, E 7373, NSC-127716, 127716, NSC 127716
    Company:
    Generic mfg.
    Drug class:
    DNMT inhibitor
    Related drugs:
    3d
    A Prospective, Single-Arm, Multicenter Clinical Study of Chidamide, Decitabine, PD-1 Monoclonal Antibody Combined with Pegaspargase (Epi-Immuno-Pe) in Elderly/Chemotherapy-Intolerant Patients with Relapsed or Refractory NK/T-Cell Lymphoma (ChiCTR2600117389)
    P=N/A, N=20, Not yet recruiting, The First Affiliated Hospital, Zhejiang University School of Medicine; The First Affiliated Hospital, Zhejiang University School of Medicine
    New trial
    |
    decitabine • Epidaza (chidamide) • Oncaspar liquid (pegaspargase)
    3d
    A prospective, multicenter, single-arm clinical study of low-dose Decitabine combined with Venetoclax in the treatment of newly diagnosed high-risk myelodysplastic syndrome patients. (ChiCTR2500114059)
    P=N/A, N=52, Not yet recruiting, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College.; Institute of Hematolog
    New trial
    |
    Venclexta (venetoclax) • decitabine
    3d
    The clinical study on individualized treatment for advanced myeloproliferative neoplasms using integrated multi-omics approaches (ChiCTR2500111453)
    P=N/A, N=10, Not yet recruiting, The Second Medical Center of Chinese PLA General Hospital​; The Second Medical Center of Chinese PLA General Hospital?
    New trial
    |
    TP53 (Tumor protein P53) • JAK2 (Janus kinase 2) • ASXL1 (ASXL Transcriptional Regulator 1) • CALR (Calreticulin)
    |
    TP53 mutation • ASXL1 mutation • EZH2 mutation
    |
    decitabine
    3d
    A prospective, multiple centers, single arm clinical study on the efficacy and safety of decitabine combined with improved TBF conditioning regimen in patients with myelodysplastic syndrome accompanied by myelofibrosis received Allogeneic hematopoietic stem cell transplantation. (ChiCTR2500114465)
    P2, N=54, Not yet recruiting, The First Affiliated Hospital of Zhejiang University, School of Medicine,; The First Affiliated Hospital of Zhejiang University, School of Medicine,
    New P2 trial
    |
    decitabine • fludarabine IV • thiotepa • busulfan
    3d
    DEMEL-1: A single-center, single-arm, phase II clinical study evaluating the efficacy and safety of Decitabine combined with low-dose Melphalan in patients with high-risk refractory myelodysplastic syndrome (ChiCTR2500115432)
    P2, N=20, Not yet recruiting, The FIrst Affiliated Hospital, College of Medicine, Zhejiang University; The FIrst Affiliated Hospital, College of Medicine, Zhejiang University
    New P2 trial
    |
    decitabine • melphalan
    3d
    A phase II clinical study evaluating the efficacy and safety of Decitabine combined with Melphalan in newly diagnosed MDS-IB (ChiCTR2500115218)
    P2, N=28, Not yet recruiting, The FIrst Affiliated Hospital, College of Medicine, Zhejiang University; The FIrst Affiliated Hospital, College of Medicine, Zhejiang University
    New P2 trial
    |
    decitabine • melphalan
    3d
    Efficacy and Safety of Ruxolitinib Combined with Decitabine in Treating High-Risk Myelofibrosis Patients: A Prospective, Multicenter, Phase II Clinical Study Protocol (ChiCTR2600117487)
    P2, N=36, Not yet recruiting, The First Affiliated Hospital of Zhejiang University School of Medicine; The First Affiliated Hospital of Zhejiang University School of Medicine
    New P2 trial
    |
    Jakafi (ruxolitinib) • decitabine
    3d
    A Prospective, Single-Center, Exploratory Study on the Efficacy and Safety of Ultra-Low-Dose Decitabine Combined with Escalating-Dose Donor Lymphocyte Infusion for Post-Transplant Relapse Prevention in Patients with Bi-allelic TP53 Mutated Myelodysplastic Syndromes (ChiCTR2500114629)
    P2, N=32, Not yet recruiting, The FIrst Affiliated Hospital, College of Medicine, Zhejiang University; The FIrst Affiliated Hospital, College of Medicine, Zhejiang University
    New P2 trial
    |
    TP53 mutation
    |
    decitabine
    5d
    Synthetic lethality of decitabine plus ATR inhibition for TP53-mutated AML. (PubMed, Blood Adv)
    Interestingly, this synergistic lethality was not observed with azacitidine or treatment with GSK3685032, a potent DNMT1 inhibitor, both of which produce a comparable level of global hypomethylation to decitabine. Treatment with decitabine and ATR inhibitor reduces leukemia burden and prolongs survival in in vivo mouse models of TP53-mutated AML. Collectively, these show that TP53 loss generates a selective vulnerability to decitabine-induced replication stress, with the combination of ATR inhibition and decitabine showing promise as a new therapeutic approach for TP53-MN.
    Journal
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation
    |
    azacitidine • decitabine
    6d
    Adoptive T Cell Therapy With DC/AML Fusion Vaccine Plus Decitabine and Venetoclax in AML (clinicaltrials.gov)
    P1, N=30, Not yet recruiting, David Avigan
    New P1 trial • First-in-human
    |
    FLT3 (Fms-related tyrosine kinase 3)
    |
    FLT3 mutation
    |
    Venclexta (venetoclax) • decitabine
    6d
    AML16: A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia (clinicaltrials.gov)
    P2, N=206, Active, not recruiting, St. Jude Children's Research Hospital | Trial primary completion date: Jun 2025 --> Sep 2025
    Trial primary completion date
    |
    sorafenib • azacitidine • etoposide IV • decitabine • daunorubicin • idarubicin hydrochloride • mitoxantrone • fludarabine IV • Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) • Neupogen (filgrastim) • dexrazoxane
    7d
    Decitabine in Combination With Standard of Care Therapy for the Treatment of Surgically Resectable HPV-Negative Head and Neck Cancer (clinicaltrials.gov)
    P1, N=24, Recruiting, Mayo Clinic | Not yet recruiting --> Recruiting
    Enrollment open
    |
    decitabine